Management of irritable bowel syndrome with diarrhea: focus on eluxadoline

References

• American Gastroenterological Association. IBS in America: survey summary findings [Internet]; 2015 [cited 2020 Nov 24]. Available from: http://www.multivu.com/players/English/7634451-aga-ibs-in-america-survey/docs/survey-findings-pdf-635473172.pdf.
   Google Scholar
• Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254–272.e11.
   PubMed Web of Science ®Google Scholar
• American College of Gastroenterology. Interactive IBS tools [Internet]; 2019 [cited 2019 Jul 22]. Available from: https://gi.org/patients/gi-health-and-disease/interactive-ibs-tools/.
   Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712–721.
   PubMed Web of Science ®Google Scholar
• Hungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365–1375.
   PubMed Web of Science ®Google Scholar
• Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151–163.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407.
   Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491.
   PubMed Web of Science ®Google Scholar
• Lin S, Mooney PD, Kurien M, et al. Prevalence, investigational pathways and diagnostic outcomes in differing irritable bowel syndrome subtypes. Eur J Gastroenterol Hepatol. 2014;26(10):1176–1180.
   PubMed Web of Science ®Google Scholar
• Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.
   PubMed Web of Science ®Google Scholar
• ten Berg MJ, Goettsch WG, van den Boom G, et al. Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol. 2006;18(5):475–481.
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Rentz A, et al. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin Ther. 2002;24(4):675–689.
   PubMed Web of Science ®Google Scholar
• Singh P, Staller K, Barshop K, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103–8109.
   PubMed Web of Science ®Google Scholar
• Lackner JM, Ma C-X, Keefer L, et al. Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11(9):1147–1157.
   PubMed Web of Science ®Google Scholar
• Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(9):1023–1034.
   PubMed Web of Science ®Google Scholar
• Buono JL, Mathur K, Averitt AJ, et al. Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a U.S. commercially insured population. J Manag Care Spec Pharm. 2017;23(4):453–460.
   PubMed Web of Science ®Google Scholar
• Törnblom H, Goosey R, Wiseman G, et al. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: results from patient and healthcare professional surveys. United European Gastroenterol J. 2018;6(9):1417–1427.
   PubMed Web of Science ®Google Scholar
• Flores NM, Tucker C, Carson RT, et al. The humanistic and economic burden of irritable bowel syndrome with diarrhoea (IBS-D) by disease severity among patients in the EU5 region. Value Health. 2016;19(7):A514–A515.
   Web of Science ®Google Scholar
• Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011;106(10):1749–1759.
   PubMed Web of Science ®Google Scholar
• Rangan V, Ballou S, Shin A, Beth Israel Deaconess Medical Center GI Motility Working Group, et al. Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America Survey. Gastroenterology. 2020;158(3):786–788.e1.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Mearin F, Azpiroz F, et al. Irritable bowel syndrome diagnosis and management: a simplified algorithm for clinical practice. United European Gastroenterol J. 2017;5(6):773–788.
   PubMed Web of Science ®Google Scholar
• Wedlake L, A’Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30(7):707–717.
   PubMed Web of Science ®Google Scholar
• Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42(1):3–11.
   PubMed Web of Science ®Google Scholar
• Carrasco-Labra A, Lytvyn L, Falck-Ytter Y, et al. AGA technical review on the evaluation of functional diarrhea and diarrhea-predominant irritable bowel syndrome in adults (IBS-D). Gastroenterology. 2019;157(3):859–880.
   PubMed Web of Science ®Google Scholar
• Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133–146.
   PubMed Web of Science ®Google Scholar
• Drossman DA. Abuse, trauma, and GI illness: is there a link? Am J Gastroenterol. 2011;106(1):14–25.
   PubMed Web of Science ®Google Scholar
• Lembo A, Zaman M, Jones M, et al. Influence of genetics on irritable bowel syndrome, gastro-oesophageal reflux and dyspepsia: a twin study. Aliment Pharmacol Ther. 2007;25(11):1343–1350.
   PubMed Web of Science ®Google Scholar
• Ek WE, Reznichenko A, Ripke S, et al. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut. 2015;64(11):1774–1782.
   PubMed Web of Science ®Google Scholar
• Simrén M, Barbara G, Flint HJ, Rome Foundation Committee, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–176.
   PubMed Web of Science ®Google Scholar
• Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46(4):421–431.
   PubMed Web of Science ®Google Scholar
• Morales W, Rezaie A, Barlow G, et al. Second-generation biomarker testing for irritable bowel syndrome using plasma anti-CdtB and anti-vinculin levels. Dig Dis Sci. 2019;64(11):3115–3121.
   PubMed Web of Science ®Google Scholar
• Palsson OS, Whitehead WE, van Tilburg MAL, et al. Development and validation of the Rome IV Diagnostic Questionnaire for adults. Gastroenterology. 2016;150(6):1481–1491.
   Web of Science ®Google Scholar
• Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Chey WD, ACG Task Force on Management of Irritable Bowel Syndrome, et al. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018;113(Suppl 2):1–18.
   PubMed Web of Science ®Google Scholar
• Weinberg DS, Smalley W, Heidelbaugh JJ, American Gastroenterological Association, et al. American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014;147(5):1146–1148.
   PubMed Web of Science ®Google Scholar
• Aziz I, Trott N, Briggs R, et al. Efficacy of a gluten-free diet in subjects with irritable bowel syndrome-diarrhea unaware of their HLA-DQ2/8 genotype. Clin Gastroenterol Hepatol. 2016;14(5):696–703:e1.
   PubMed Web of Science ®Google Scholar
• Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011;106(3):508–514.
   PubMed Web of Science ®Google Scholar
• Biesiekierski JR, Peters SL, Newnham ED, et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology. 2013;145(2):320–328.
   PubMed Web of Science ®Google Scholar
• de Roest RH, Dobbs BR, Chapman BA, et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. Int J Clin Pract. 2013;67(9):895–903.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67–75.
   PubMed Web of Science ®Google Scholar
• Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399–1407.
   PubMed Web of Science ®Google Scholar
• Halmos EP, Christophersen CT, Bird AR, et al. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93–100.
   PubMed Web of Science ®Google Scholar
• Eswaran S, Chey WD, Jackson K, et al. A diet low in fermentable oligo-, di-, and monosaccharides and polyols improves quality of life and reduces activity impairment in patients with irritable bowel syndrome and diarrhea. Clin Gastroenterol Hepatol. 2017;15(12):1890–1899.
   PubMed Web of Science ®Google Scholar
• Staudacher HM, Lomer MCE, Anderson JL, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510–1518.
   PubMed Web of Science ®Google Scholar
• Staudacher HM, Whelan K, Irving PM, et al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24(5):487–495.
   PubMed Web of Science ®Google Scholar
• Lacy BE. The science, evidence, and practice of dietary interventions in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2015;13(11):1899–1906.
   PubMed Web of Science ®Google Scholar
• Wang B, Duan R, Duan L. Prevalence of sleep disorder in irritable bowel syndrome: a systematic review with meta-analysis. Saudi J Gastroenterol. 2018;24(3):141–150.
   PubMed Web of Science ®Google Scholar
• Patel A, Hasak S, Cassell B, et al. Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44(3):246–258.
   PubMed Web of Science ®Google Scholar
• Buchanan DT, Cain K, Heitkemper M, et al. Sleep measures predict next-day symptoms in women with irritable bowel syndrome. J Clin Sleep Med. 2014;10(9):1003–1009.
   PubMed Web of Science ®Google Scholar
• Lackner JM, Jaccard J, Keefer L, et al. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018;155(1):47–57.
   PubMed Web of Science ®Google Scholar
• Johannesson E, Ringström G, Abrahamsson H, et al. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015;21(2):600–608.
   PubMed Web of Science ®Google Scholar
• Johannesson E, Simrén M, Strid H, et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011;106(5):915–922.
   PubMed Web of Science ®Google Scholar
• Zheng H, Li Y, Zhang W, et al. Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: a randomized controlled trial. Medicine (Baltimore). 2016;95(24):e3884.
   PubMed Web of Science ®Google Scholar
• Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 1987;130:81–84.
   PubMedGoogle Scholar
• Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80.
   PubMedGoogle Scholar
• US Food and Drug Administration. Drug safety communications: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse [Internet]; 2016 [cited 2020 Oct 1]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM505108.pdf.
   Google Scholar
• Akel T, Bekheit S. Loperamide cardiotoxicity: "A brief review". Ann Noninvasive Electrocardiol. 2018;23(2):e12505.
   PubMed Web of Science ®Google Scholar
• Vidarsdottir H, Vidarsdottir H, Moller PH, et al. Loperamide-induced acute pancreatitis. Case Rep Gastrointest Med. 2013;2013:517414.
   PubMedGoogle Scholar
• Dierksen J, Gonsoulin M, Walterscheid JP. Poor man's methadone: a case report of loperamide toxicity. Am J Forensic Med Pathol. 2015;36(4):268–270.
   PubMed Web of Science ®Google Scholar
• MacDonald R, Heiner J, Villarreal J, et al. Loperamide dependence and abuse. BMJ Case Rep. 2015;2015:bcr2015209705.
   PubMedGoogle Scholar
• Stanciu CN, Gnanasegaram SA. Loperamide, the "poor man's methadone": brief review. J Psychoactive Drugs. 2017;49(1):18–21.
   PubMed Web of Science ®Google Scholar
• Didari T, Mozaffari S, Nikfar S, et al. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol. 2015;21(10):3072–3084.
   PubMed Web of Science ®Google Scholar
• Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48(6):505–512.
   PubMed Web of Science ®Google Scholar
• Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2016;61(2):560–571.
   PubMed Web of Science ®Google Scholar
• Lacy BE. Review article: an analysis of safety profiles of treatments for diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(8):817–830.
   PubMed Web of Science ®Google Scholar
• Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol. 1981;3(2):153–156.
   PubMed Web of Science ®Google Scholar
• Hadley SK, Gaarder SM. Treatment of irritable bowel syndrome. Am Fam Physician. 2005;72(12):2501–2506.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. LOTRONEX (alosetron hydrochloride) tablets: risk evaluation and mitigation strategy [Internet]; 2016 [cited 2016 Feb 16]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/rems/Lotronex_2016-01-07_REMS_Document%20.pdf.
   Google Scholar
• Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000;355(9209):1035–1040.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161(14):1733–1740.
   PubMedGoogle Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242–253.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Viberzi. Highlights of prescribing information [Internet]; 2020 [cited 2020 July 27]. Available from: https://www.allergan.com/assets/pdf/viberzi_pi.
   Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32.
   PubMed Web of Science ®Google Scholar
• Schoenfeld P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161–1168.
   PubMed Web of Science ®Google Scholar
• Böhn L, Störsrud S, Törnblom H, et al. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. Am J Gastroenterol. 2013;108(5):634–641.
   PubMed Web of Science ®Google Scholar
• Simrén M, Månsson A, Langkilde AM, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion. 2001;63(2):108–115.
   PubMed Web of Science ®Google Scholar
• Nagarajan N, Morden A, Bischof D, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27(9):1002–1010.
   PubMed Web of Science ®Google Scholar
• De Giorgio R, Volta U, Gibson PR. Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction? Gut. 2016;65(1):169–178.
   PubMed Web of Science ®Google Scholar
• Werlang ME, Palmer WC, Lacy BE. Irritable bowel syndrome and dietary interventions. Gastroenterol Hepatol (NY). 2019;15(1):16–26.
   PubMedGoogle Scholar
• American Gastroenterological Association. Low-FODMAP diet [Internet]; 2019 [cited 2019 Jan 21]. Available from: https://www.gastro.org/practice-guidance/gi-patient-center/topic/low-fodmap-diet.
   Google Scholar
• Schiller LR, Santa Ana CA, Morawski SG, et al. Mechanism of the antidiarrheal effect of loperamide. Gastroenterology. 1984;86(6):1475–1480.
   PubMed Web of Science ®Google Scholar
• Barr W, Smith A. Acute diarrhea in adults. Am Fam Physician. 2014;89(3):180–189.
   PubMed Web of Science ®Google Scholar
• Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol. 1996;31(5):463–468.
   PubMed Web of Science ®Google Scholar
• Ford AC, Lacy BE, Talley NJ. Irritable bowel syndrome. N Engl J Med. 2017;376(26):2566–2578.
   PubMed Web of Science ®Google Scholar
• Cash BD. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome. Curr Med Res Opin. 2014;30(7):1405–1415.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Chey WD. Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. Rev Gastroenterol Disord. 2009;9(1):7–15.
   PubMedGoogle Scholar
• O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541–551.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–1561.
   PubMed Web of Science ®Google Scholar
• Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–1590.
   PubMed Web of Science ®Google Scholar
• Weerts ZZRM, Masclee AAM, Witteman BJM, et al. Efficacy and safety of peppermint oil in a randomized, double-blind trial of patients with irritable bowel syndrome. Gastroenterology. 2020;158(1):123–136.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Tack J, Ford AC, et al. Neuromodulators for functional gastrointestinal disorders (disorders of Gut-Brain Interaction): A Rome Foundation working team report. Gastroenterology. 2018;154(4):1140–1171.e1.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41(5):438–448.
   PubMed Web of Science ®Google Scholar
• Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex. 2012;77(2):82–90.
   PubMedGoogle Scholar
• Salix Pharmaceuticals Inc. Xifaxan. Highlights of prescribing information [Internet]; 2018 [cited 2019 Jun 6]. Available from: https://shared.salix.com/shared/pi/xifaxan550-pi.pdf.
   Google Scholar
• Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113–1121.
   PubMed Web of Science ®Google Scholar
• Pimentel M, Cash BD, Lembo A, et al. Repeat rifaximin for irritable bowel syndrome: no clinically significant changes in stool microbial antibiotic sensitivity. Dig Dis Sci. 2017;62(9):2455–2463.
   PubMed Web of Science ®Google Scholar
• Black CJ, Burr NE, Camilleri M, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2019;69(1):78–82.
   Web of Science ®Google Scholar
• Sebela Pharmaceuticals. Lotronex. Highlights of prescribing information [Internet]; 2016 [cited 2020 Jul 27]. Available from: https://sebelapharma.com/wp-content/uploads/2018/08/lotronex-pi.pdf.
   Google Scholar
• Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96(9):2662–2670.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Eluxadoline: first global approval. Drugs. 2015;75(11):1305–1310.
   PubMed Web of Science ®Google Scholar
• Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17–44.
   PubMed Web of Science ®Google Scholar
• Ananthan S. Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics. AAPS J. 2006;8(1):E118–E125.
   PubMed Web of Science ®Google Scholar
• Wade PR, Palmer JM, McKenney S, et al. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/µ opioid receptor antagonist. Br J Pharmacol. 2012;167(5):1111–1125.
   PubMed Web of Science ®Google Scholar
• Abdelhamid EE, Sultana M, Portoghese PS, et al. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. J Pharmacol Exp Ther. 1991;258(1):299–303.
   PubMed Web of Science ®Google Scholar
• Hughes PA, Castro J, Harrington AM, et al. Increased κ-opioid receptor expression and function during chronic visceral hypersensitivity. Gut. 2014;63(7):1199–1200.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Dove LS, Andrae DA, et al. Radar plots: a novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. Neurogastroenterol Motil. 2018;30(8):e13331.
   Web of Science ®Google Scholar
• Lacy BE, Harris LA, Chang L, et al. Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials. eCollection 2019 [Epub Ahead of Print]. 2019;12:1–12.
   Google Scholar
• Lacy BE, Chey WD, Cash BD, et al. Eluxadoline efficacy in IBS-D patients who report prior loperamide use. Am J Gastroenterol. 2017;112(6):924–932.
   PubMed Web of Science ®Google Scholar
• Brenner DM, Gutman C, Jo E. Efficacy and safety of eluxadoline in IBS-D patients who report inadequate symptom control with prior loperamide use: a Phase 4, multicenter, multinational, randomized, placebo-controlled, double-blinded study (RELIEF). Poster presentation P0344: American College of Gastroenterology Annual Scientific Meeting, Philadelphia, Pennsylvania, USA, October 5–10, 2018.
   Google Scholar
• Zhu L, Huang D, Shi L, et al. Intestinal symptoms and psychological factors jointly affect quality of life of patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2015;13(1):49.
   PubMed Web of Science ®Google Scholar
• Andrae DA, Patrick DL, Drossman DA, et al. Evaluation of the Irritable Bowel Syndrome Quality of Life (IBS-QOL) questionnaire in diarrheal-predominant irritable bowel syndrome patients. Health Qual Life Outcomes. 2013;11:208.
   PubMed Web of Science ®Google Scholar
• Abel JL, Carson RT, Andrae DA. The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea. Qual Life Res. 2019;28(2):369–377.
   PubMed Web of Science ®Google Scholar
• Cash BD, Lacy BE, Schoenfeld PS, et al. Safety of eluxadoline in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2017;112(2):365–374.
   PubMed Web of Science ®Google Scholar
• US Drug Enforcement Administration. Schedules of controlled substances: placement of eluxadoline into schedule IV. Notice of proposed rulemaking. Fed Regist. 2015;80(154):48044–48051.
   Google Scholar
• Levy-Cooperman N, McIntyre G, Bonifacio L, et al. Abuse potential and pharmacodynamic characteristics of oral and intranasal eluxadoline, a mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist. J Pharmacol Exp Ther. 2016;359(3):471–481.
   PubMed Web of Science ®Google Scholar
• Fant RV, Henningfield JE, Cash BD, et al. Eluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2017;15(7):1021–1029.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA drug safety communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder [Internet]; 2017 [cited 2020 Sep 3]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm.
   Google Scholar
• Harinstein L, Wu E, Brinker A. Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder. Aliment Pharmacol Ther. 2018;47(6):809–815.
   PubMed Web of Science ®Google Scholar
• McLoughlin MT, Mitchell RM. Sphincter of Oddi dysfunction and pancreatitis. World J Gastroenterol. 2007;13(47):6333–6343.
   PubMed Web of Science ®Google Scholar
• Marbury TC, Berg JK, Dove LS, et al. Effect of hepatic impairment on eluxadoline pharmacokinetics. J Clin Pharmacol. 2017;57(11):1454–1459.
   PubMed Web of Science ®Google Scholar
• Levio S, Cash BD. The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol. 2017;10(9):715–725.
   PubMed Web of Science ®Google Scholar
• Lacy BE. Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med. 2016;9:7–17.
   PubMed Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(suppl 1):S2–S26.
   PubMed Web of Science ®Google Scholar
• World Gastroentrology Organisation. World Gastroenterology Organisation global guidelines: irritable bowel syndrome: a global perspective [Internet]; 2015 [cited 2020 Oct 1]. Available from: https://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs/irritable-bowel-syndrome-ibs-english.
   Google Scholar